Abstract

Much of our work focuses on understanding and targeting the tumour microenvironment, TME, of high-grade serous ovarian cancer, HGSOC. We aim to find ways to eradicate the peritoneal metastases that arise early in this disease, recur after chemotherapy and are ultimately lethal. We are using our extensive knowledge of human HGSOC metastases and a platform of clinically relevant mouse and human models that replicate the genetics and TME of the human cancer.